Citation Impact
Citing Papers
Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy
2015 StandoutScience
Programmed cell death 1 ligand 1 and tumor-infiltrating CD8 + T lymphocytes are prognostic factors of human ovarian cancer
2007 StandoutNobel
PD-1 + regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer
2019 StandoutNobel
PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity
2017 StandoutNature
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
2017 Standout
Elements of cancer immunity and the cancer–immune set point
2017 StandoutNature
A view on drug resistance in cancer
2019 StandoutNature
The biology and management of non-small cell lung cancer
2018 StandoutNature
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
2014 StandoutNature
Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity
2015 Standout
Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2017 Standout
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
2017 Standout
Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential
2015 StandoutNobel
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
2016 Standout
Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination
2016
Tumour heterogeneity and cancer cell plasticity
2013 StandoutNature
Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors
2016
Renal complications of immune checkpoint blockade
2016
Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression
2015 Standout
Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy
2016
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
2017 Standout
The causes and consequences of genetic heterogeneity in cancer evolution
2013 StandoutNature
Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies
2015
The blockade of immune checkpoints in cancer immunotherapy
2012 Standout
Management of toxicities of immune checkpoint inhibitors
2016
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
2015 StandoutNature
AKT/PKB Signaling: Navigating the Network
2017 Standout
Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade
2017 StandoutNobel
Metastatic colonization by circulating tumour cells
2016 StandoutNature
Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy
2016 StandoutNobel
Hyperprogressive disease: recognizing a novel pattern to improve patient management
2018
Computational design of a synthetic PD-1 agonist
2021 StandoutNobel
Establishment of NOD-Pdcd1-/-mice as an efficient animal model of type I diabetes
2005 StandoutNobel
PD-1 Inhibits Antiviral Immunity at the Effector Phase in the Liver
2003 StandoutNobel
Managing Immune Checkpoint-Blocking Antibody Side Effects
2015
Adoptive cell transfer as personalized immunotherapy for human cancer
2015 StandoutScience
Nonoverlapping roles of PD-1 and FoxP3 in maintaining immune tolerance in a novel autoimmune pancreatitis mouse model
2016 StandoutNobel
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
2018 Standout
Hypoxia-inducible factor 1-dependent expression of adenosine receptor 2B promotes breast cancer stem cell enrichment
2018 StandoutNobel
The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors
2008 StandoutNobel
Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients
2008 StandoutNobel
Chemotherapy induces enrichment of CD47 + /CD73 + /PDL1 + immune evasive triple-negative breast cancer cells
2018 StandoutNobel
The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patients
2018 StandoutScience
PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells
2003 StandoutNobel
Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodies
2016
Clinical and Histologic Features of Lichenoid Mucocutaneous Eruptions Due to Anti–Programmed Cell Death 1 and Anti–Programmed Cell Death Ligand 1 Immunotherapy
2016
Unique potential of 4-1BB agonist antibody to promote durable regression of HPV + tumors when combined with an E6/E7 peptide vaccine
2015 StandoutNobel
Cancer Genome Landscapes
2013 StandoutScience
Precision glycocalyx editing as a strategy for cancer immunotherapy
2016 StandoutNobel
PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine
2001 StandoutNobel
Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities
2016 StandoutNobel
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
2014 Standout
HIF-1 regulates CD47 expression in breast cancer cells to promote evasion of phagocytosis and maintenance of cancer stem cells
2015 StandoutNobel
Chemotherapy triggers HIF-1–dependent glutathione synthesis and copper chelation that induces the breast cancer stem cell phenotype
2015 StandoutNobel
CAR T cell immunotherapy for human cancer
2018 StandoutScience
Immune Checkpoint Blockade in Cancer Therapy
2015 Standout
Cancer immunotherapy using checkpoint blockade
2018 StandoutScience
Signalling to eIF4E in cancer
2015
Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade
2002 StandoutNobel
Diverse types of dermatologic toxicities from immune checkpoint blockade therapy
2016
N‐Carboxyanhydride Polymerization of Glycopolypeptides That Activate Antigen‐Presenting Cells through Dectin‐1 and Dectin‐2
2018 StandoutNobel
Works of M. Thomas being referenced
Secondary Tumors Arising in Patients Undergoing BRAF Inhibitor Therapy Exhibit Increased BRAF–CRAF Heterodimerization
2016
Kidney injuries related to ipilimumab
2014
eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies
2014 Nature
Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab
2015